Suppr超能文献

移植前单克隆丙种球蛋白血症的肾移植患者的初步生存数据。

Initial survival data of kidney transplant patients with pre-transplant monoclonal gammopathy.

机构信息

Department of Surgery, The Methodist J.C. Walter Jr. Transplant Center, The Methodist Hospital, Houston, TX 77030, USA.

出版信息

Clin Transplant. 2012 Mar-Apr;26(2):300-4. doi: 10.1111/j.1399-0012.2011.01539.x. Epub 2011 Nov 2.

Abstract

BACKGROUND

Monoclonal gammopathy of undetermined significance (MGUS) is the presence of a serum monoclonal protein at a concentration of <3 g/dL without evidence of lymphoproliferative disease or organ damage. The prevalence of MGUS in kidney transplantation (KT) candidates is unknown. The present is a retrospective report of patients who underwent evaluation for a KT and were found to have MGUS at our center.

METHODS

All transplant candidates found to have MGUS between the years 2000 and 2007 were included. Variables were collected. Patients with MGUS that received a KT were compared with patients with MGUS that were not transplanted.

RESULTS

Of a total of 1215 KT candidates, 34 were found to have MGUS during the KT evaluation. Nine patients with MGUS were transplanted. Myeloma or lymphoproliferative disease was not observed. Following transplantation, the MGUS group had a lower survival than the non-transplanted group. However, survival from the time of MGUS diagnosis was not different between the transplanted and non-transplanted MGUS groups.

CONCLUSIONS

In this group, transplantation did not confer a survival benefit. It is our hope that these initial data will serve as a platform for future studies. We suggest MGUS screening in all patients older than 50 yr of age undergoing evaluation for transplantation.

摘要

背景

意义未明的单克隆丙种球蛋白血症(MGUS)是指血清中单克隆蛋白浓度<3 g/dL,无淋巴增殖性疾病或器官损害证据。MGUS 在肾移植(KT)候选者中的患病率尚不清楚。本研究回顾性报告了在我们中心接受 KT 评估且发现 MGUS 的患者。

方法

纳入 2000 年至 2007 年间发现 MGUS 的所有移植候选者。收集变量。比较 MGUS 接受 KT 的患者与未接受移植的 MGUS 患者。

结果

在总共 1215 名 KT 候选者中,有 34 名在 KT 评估期间发现 MGUS。9 名 MGUS 患者接受了移植。未观察到骨髓瘤或淋巴增殖性疾病。移植后,MGUS 组的生存率低于未移植组。然而,从 MGUS 诊断时起,移植和未移植 MGUS 组的生存率没有差异。

结论

在该组中,移植并未带来生存获益。我们希望这些初步数据将成为未来研究的平台。我们建议对所有 50 岁以上接受移植评估的患者进行 MGUS 筛查。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验